[1]徐双年,陈洁平,刘建平,等.三氧化二砷与全反式维甲酸治疗急性早幼粒细胞白血病疗效比较的系统评价[J].第三军医大学学报,2009,31(21):2098-2102.
 XU Shuang-nian,CHEN Jie-ping,LIU Jian-ping,et al.Arsenic trioxide vs all-trans retinoic acid to treat acute promyelocytic leukemia: a systematic comparative review[J].J Third Mil Med Univ,2009,31(21):2098-2102.
点击复制

三氧化二砷与全反式维甲酸治疗急性早幼粒细胞白血病疗效比较的系统评价(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
31卷
期数:
2009年第21期
页码:
2098-2102
栏目:
论著
出版日期:
2009-11-15

文章信息/Info

Title:
Arsenic trioxide vs all-trans retinoic acid to treat acute promyelocytic leukemia: a systematic comparative review
作者:
徐双年陈洁平刘建平夏芸
第三军医大学西南医院血液病中心;北京中医药大学循证医学中心
Author(s):
XU Shuang-nian CHEN Jie-ping LIU Jian-ping XIA Yun
Center for Hematology, Southwest Hospital, Third Military Medical University, Chongqing 400038; Center for Evidence-Based Medicine, Beijing University of Chinese Medicine, Beijing 100029, China
关键词:
三氧化二砷白血病早幼粒细胞急性随机对照试验系统评价
Keywords:
arsenic trioxide acute promyelocytic leukemia randomized controlled trials systematic review
分类号:
R195.4;R733.71;R979.1
文献标志码:
A
摘要:
目的   比较三氧化二砷(arsenic trioxide, ATO)与全反式维甲酸(all-trans retinoic acid, ATRA)治疗急性早幼粒细胞白血病(acute promyelocytic leukemua,APL)的疗效与安全性。   方法   采用Cochrane系统评价方法,检索Cochrane图书馆及其临床对照试验数据库、MEDLINE、EMBASE、CBM、CNKI和CMAC,并辅以手工检索,检索时间截至2009年3月。获取比较ATO和ATRA治疗APL疗效的随机对照试验文献,以完全缓解率、总生存率、无病生存率、治疗开始到获得缓解的时间、复发率、病死率及治疗相关副反应为结局评价指标,使用Cochrane协作网Revman 5.0软件进行Meta分析。   结果   共鉴定并纳入4项随机对照试验研究(RCT),共包括243例APL患者,研究的偏倚风险评估全部为中等程度偏倚,研究目的均为比较ATO与ATRA治疗APL的疗效和副反应发生情况。Meta分析结果显示,ATO与ATRA治疗初治APL比较,针对CR、复发率、病死率等结局指标差异无统计学意义(P>0.05),以上各结局指标的比值比(OR)及其95%CI分别为0.96(0.50~1.86)、0.86(0.45~1.63)和1.15(0.45~2.95);开始治疗到获得CR的时间结局指标差异无统计学意义(P>0.05),均数差值及其95%CI为0.60 d(-12.34~13.53);无病生存率的比较差异也无统计学意义(P>0.05),风险比率(HR)及其95%CI为2.76(0.71~10.66)。针对肝功能异常发生率结局指标比较的OR及其95%CI为3.03(1.25~7.37),差异有统计学意义(P=0.01)。   结论   Meta分析结果提示,采用ATO治疗初治APL患者与ATRA疗效相当,但ATO可能导致肝功能异常的发生率增加。
Abstract:
Objective   To compare the efficacy and safety of arsenic trioxide (ATO) with all-trans retinoic acid (ATRA) for the treatment of acute promyelocytic leukemia (APL).   Methods   We searched the database of Cochrane Library (Issue 1, 2009), CENTRAL (1970 to 2009), Medline (1978 to 2008), EMBASE (1950 to 2009), CBM (1978 to 2008), CNKI (1994 to 2008) and CMAC (1994 to 2008). We also searched the Meta register, Conference Proceedings of American Society of Hematology (1946 to 2008) and American Society of Clinical Oncology (2004 to 2008) on the internet for grey literature. We had searched the related journals in the library of Third Military Medical University, too. We included randomized controlled trials which compared ATO with ATRA for the treatment of APL. We adopt complete remission rate, overall survival rate, disease-free survival rate, time to complete remission, relapse rate, mortality and adverse reactions as result indicators. Data were entered and analyzed with the Cochrane review manager software (Revman 5.0).   Results   Four eligible randomized controlled trials (RCTs) were included (n=243). All the RCTs were methodologically graded as B. They all are focusing on the comparison of ATO monotherapy with ATRA monotherapy in treating newly diagnosed APL patients. Meta analysis showed that effect index for complete remission, 2-year disease-free survival, time to complete remission, relapse rate and mortality was 0.96 (0.50, 1.86), 2.76 (0.71, 10.66), -1.30 d (-1.83, -0.78), 0.86 (0.45, 1.63), and 1.15 (0.45, 2.95), respectively. All indicated no statistically significant difference. Effect index for incidence of liver dysfunction was 3.03 (1.25, 7.37), which showed statistically significant difference between ATO group and ATRA group.   Conclusion   ATO is not superior to ATRA in treating newly diagnosed APL patients regarding complete remission, disease-free survival rate, time to complete remission, relapse rate and mortality. What is worse, it will increase the incidence of liver dysfunction during treatment. Due to limitation of included trials, this conclusion need to be validated by further studies.

相似文献/References:

[1]金世龙,余天雾,黄中荣,等.As2O3在HuH7及CD13+CD133+LCSCs增殖和分化中作用的初步观察[J].第三军医大学学报,2012,34(18):1857.
 Jin Shilong,Yu Tianwu,Huang Zhongrong,et al.Role of arsenic trioxide in proliferation of HuH7 cells and differentiation of CD13+CD133+ LCSCs[J].J Third Mil Med Univ,2012,34(21):1857.
[2]张佳思,廖建梅,阮潜瑛.口含低温活性银离子抗菌液预防白血病患者化疗致口腔溃疡的观察[J].第三军医大学学报,2015,37(18):1907.
[3]袁媛,李招权,司维柯,等.Wnt5a与髓细胞白血病发生关系的研究[J].第三军医大学学报,2007,29(21):2056.
 YUAN Yuan,LI Zhao-quan,SI Wei-ke,et al.Correlation between myeloid leukemia development and Wnt5a expression[J].J Third Mil Med Univ,2007,29(21):2056.
[4]陈姝,李文,罗云,等.减低剂量Bu+Cy预处理方案进行异基因造血干细胞移植治疗白血病的效果观察[J].第三军医大学学报,2012,34(24):2442.
 Chen Shu,Li Wen,Luo Yun,et al.Therapeutic effect of allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen of Bu+Cy for leukemia[J].J Third Mil Med Univ,2012,34(21):2442.
[5]赵亮,李静,魏强,等.人PGI基因siRNA慢病毒质粒的构建及对白血病细胞增殖的影响[J].第三军医大学学报,2013,35(01):20.
 Zhao Liang,Li Jing,Wei Qiang,et al.Construction of a lentiviral vector expressing human phosphoglucose isomerase gene siRNA and its influence on leukemia cell proliferation[J].J Third Mil Med Univ,2013,35(21):20.
[6]王刚,刘利,陈杰,等.白血病细胞雄激素受体基因启动子甲基化状态的研究[J].第三军医大学学报,2007,29(10):932.
 WANG Gang,LIU Li,CHEN Jie,et al.Promoter methylation profile of androgen receptor gene in leukemic cells[J].J Third Mil Med Univ,2007,29(21):932.
[7]何鹏,骆展鹏,张伶,等.RNAi重组体抑制白血病K562细胞系中NPM1基因的表达[J].第三军医大学学报,2008,30(10):938.
 HE Peng,LUO Zhan-peng,ZHANG Ling,et al.RNA interference silencing nucleophosmin 1 inhibits NPM1 gene expression in K562 cells[J].J Third Mil Med Univ,2008,30(21):938.
[8]刘中禄,毕玉田,袁军.白藜芦醇减轻三氧化二砷所致大鼠过氧化毒性作用[J].第三军医大学学报,2008,30(18):1690.
 LIU Zhong-lu,BI Yu-tian,YUAN Jun.Resveratrol protects against peroxide toxicity in rats induced by arsenic trioxide[J].J Third Mil Med Univ,2008,30(21):1690.
[9]姚婕,张晓兵,王珏,等.白血病细胞雌激素受体多个启动子甲基化的实验研究[J].第三军医大学学报,2008,30(19):1799.
 YAO Jie,ZHANG Xiao-bing,WANG Jue,et al.Methylation profile of estrogen receptor promoters gene in leukemia cells[J].J Third Mil Med Univ,2008,30(21):1799.
[10]王甦,张晓晶,刘云鹏,等.细胞外信号调节激酶抑制剂协同蟾蜍灵诱导K562细胞凋亡[J].第三军医大学学报,2007,29(05):393.
 WANG Su,ZHANG Xiao-jing,LIU Yun-peng,et al.ERK inhibitor synergistic with bufalin induces K562 cells’ apoptosis[J].J Third Mil Med Univ,2007,29(21):393.

更新日期/Last Update: 2009-11-02